BMI View: Uzbekistan's pharmaceutical market represents an underdeveloped and potentially lucrative
market for multinational drugmakers. Firms based within the CIS States are well positioned to take
advantage of this potential given the country's dependence on imports ..."
BMI View: Non-communicable conditions will remain the leading contributors to Uzbekistan's burden of
disease. Nevertheless, the country will be challenged in managing a tuberculosis epidemic and improving
its relatively poor prognosis for infectious diseases control. ..."
BMI View: Uzbekistan's healthcare system will continue to suffer from human resource constraints,
impeding improvements in healthcare outcomes in the long term. Drugmakers focused on infectious and
communicable diseases can expect to see continued revenue growth given ..."
BMI View: Pharmaceutical sales in Uzbekistan will continue to expand over the forecast period, creating
opportunities for drugmakers. Meanwhile, the Uzbek government will continue to improve the domestic
business environment through regulatory developments, privatisat ..."
BMI View: Weaker remittances inflows from expats working in Russia will reduce households' disposable
incomes in Uzbekistan, and we expect this will impact out-of-pocket pharmaceutical spending. Nevertheless,
the expansion of healthcare spending by the government will ..."
BMI View: Economic growth will allow the Uzbek government to sustain the expansive trend in healthcare
investment and expenditure over the next years. Rising wages and private consumption will also contribute
to drive pharmaceutical and healthcare sector growth, albei ..."
BMI View: The Uzbek government has made progress with its aim of increasing pharmaceutical exports in
recent months, as the country continues to develop trade relations with India. However, very little
development of either the pharmaceutical or healthcare sectors can ..."
BMI View: There have been a number of positive developments in international cooperation for
Uzbekistan's pharmaceutical sector in recent months. Having identified the pharmaceutical sector as a key
area of economic growth, the Uzbek government has been encouraging do ..."
BMI View: Our projections for the Uzbek pharmaceutical and healthcare markets going into 2014 are
broadly bearish. The country continues to rank as the least attractive in the region in our RRR ratings
matrix, and real GDP growth is set to decline. We note that there ..."
BMI View: As the most populous state in Central Asia, with a population expected to increase to 29.8mn by
2017, we expect interest in the pharmaceutical and healthcare markets to increase. However, Uzbekistan
has a number of obstacles to overcome before it will presen ..."